Viewing Study NCT02562950


Ignite Creation Date: 2025-12-24 @ 4:46 PM
Ignite Modification Date: 2026-02-25 @ 5:34 PM
Study NCT ID: NCT02562950
Status: COMPLETED
Last Update Posted: 2015-10-23
First Post: 2015-09-23
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects
Sponsor: Galapagos NV
Organization:

Study Overview

Official Title: A Phase I, Open Interaction Study Between Oral Doses of GLPG1837 and Single Doses of Midazolam in Healthy Male Subjects
Status: COMPLETED
Status Verified Date: 2015-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This will be a drug-drug interaction study to evaluate the effect of multiple oral doses of GLPG1837 on the single dose pharmacokinetic profile of midazolam administered in fed healthy male subjects. Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions: on Day 1, before dosing with GLPG1837 and on Day 12 co-administered with GLPG1837, after multiple oral doses of GLPG1837 (daily for 10 days, from Day 2 until Day 11).

Also, the safety and tolerability of multiple oral doses of GLPG1837 co-administered with midazolam in healthy male subjects will be evaluated.

A first dose group of 12 subjects will receive a total daily dose of 500 mg (250 mg b.i.d.) GLPG1837 and a second dose group of 12 subjects will receive a total daily dose of 1000 mg (500 mg b.i.d.) GLPG1837.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2015-002517-29 EUDRACT_NUMBER None View